You keep seeing ads for compounded semaglutide at prices that sound too easy. They show up on social media and land in your inbox. The pitch feels fast, simple, and low on details.
So you are left unsure about what you are looking at. Is it the same as Wegovy® or Ozempic®? Is it legal now, and is it safe?
This guide answers that in everyday words. You will learn what compounded GLP-1 is, what the FDA says about it today, and why the words “not FDA-approved” carry so much weight.
KEY TAKEAWAYS
- Compounded semaglutide and tirzepatide are not FDA-approved, and not a generic of Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.
- The FDA says compounded drugs skip its review for safety, effectiveness, and quality before sale.
- Tirzepatide came off the FDA shortage list in December 2024, and semaglutide in February 2025.
- With the shortage over, the FDA ended its pause on action against most GLP-1 compounding in 2025.
- Trial results like STEP 1 belong to the FDA-approved brands, not to compounded copies.
What readers want to figure out?
- You want to know what compounded semaglutide actually is.
- You want to know if it is the same as Wegovy® or Ozempic®.
- You want to know what the FDA says about it in 2026.
- You want to understand the safety warnings the FDA has issued.
- You want to know why “not FDA-approved” is such a big deal.
What compounded GLP-1 actually is?
Compounding is when a licensed pharmacy mixes a drug to order. A compounded GLP-1 is semaglutide or tirzepatide made this way. The original drugmaker does not make these versions.
Here is the label to keep in mind. These are compounded semaglutide and tirzepatide (not FDA-approved; not a generic of Wegovy®, Ozempic®, Mounjaro®, or Zepbound®).
Two kinds of pharmacies make them. A 503A pharmacy fills one prescription for one person. A 503B outsourcing facility makes larger batches.
That is the short version of the setup. For the full difference between compounded and approved drugs, see the general explainer at /learn/compounded-vs-fda-approved/.
Compounded semaglutide is not a generic of Wegovy® or Ozempic®. It is a different kind of product with different rules.
How compounded GLP-1 is usually sold?
Most people meet these products online. A telehealth site pairs a short intake form with a prescription. A compounding pharmacy then ships the shot to your door.
The format often differs from the brands. Many compounded versions arrive in a vial with a separate syringe. The FDA-approved brands usually come in a prefilled pen.
That difference is part of the dosing risk. With a vial and syringe, you measure each dose yourself. A small mistake in the math can mean too much or too little.
Some sites also offer custom mixes or doses. The FDA has looked at blends like semaglutide with vitamin B12. It still counts many of these as copies of the approved drug.
Why compounded GLP-1 surged during the shortage?
The story starts with a shortage. Semaglutide and tirzepatide went into shortage in 2022. Demand was simply higher than supply.
Interest in GLP-1 medicines climbed fast in those years. People wanted help with weight and with blood sugar. When the brands ran short, compounded versions filled the gap.
The law has a narrow exception here. While a drug sits on the FDA shortage list, pharmacies may compound a copy under limited rules. That opened the door.
So telehealth sites began offering compounded versions quickly. Many people first heard of compounded semaglutide during this window. The ads are still common today.
What the FDA says now, in 2026?
The shortage is the part that changed. The FDA declared the tirzepatide shortage resolved on December 19, 2024. It declared the semaglutide shortage resolved on February 21, 2025.
That shift matters for compounding. Once a drug leaves the shortage list, the copy exception mostly closes. The FDA calls a near-identical compound “essentially a copy” of the approved drug.
The agency then set end dates for its pause on enforcement. For semaglutide, the pause for pharmacies ended April 22, 2025. For outsourcing facilities, it ended May 22, 2025.
Tirzepatide followed the same path a bit earlier. The pause for pharmacies ended in February 2025. For outsourcing facilities, it ended March 19, 2025.
Here is where things stand in 2026. Tirzepatide and semaglutide are not on the FDA shortage list. They are also not on the 503B bulks list.
| FDA action on GLP-1 compounding | Tirzepatide | Semaglutide |
|---|---|---|
| Shortage declared resolved | December 19, 2024 | February 21, 2025 |
| Pharmacy (503A) pause ended | February 18, 2025 | April 22, 2025 |
| Outsourcing facility (503B) pause ended | March 19, 2025 | May 22, 2025 |
| On FDA shortage list in 2026? | No | No |
| On 503B bulks list in 2026? | No | No |
When compounding is still allowed?
The rules are not a total ban. The FDA says compounded drugs still have a place. They should be used when an FDA-approved drug cannot meet a patient’s medical need.
There is also a narrow exception on copies. A prescriber can note a real, documented difference that matters for one patient. That specific case can support a compounded version.
The line is about scale and need. The FDA has said it does not plan to act when a pharmacy fills four or fewer such prescriptions in a month. Your clinician and pharmacy handle these details.
The FDA’s safety warnings on compounded GLP-1
The FDA has posted clear concerns about these products. Its main message is simple. Compounded drugs are not FDA-approved, so the agency does not check them for safety, effectiveness, or quality before sale.
Dosing is a top worry. The FDA received reports of adverse events, some needing a hospital visit. Many were tied to dosing errors, where people or providers measured the wrong amount.
The reports have added up over time. As of May 31, 2026, the FDA had logged 990 adverse-event reports for compounded semaglutide. It logged more than 730 for compounded tirzepatide.
One point about those counts is easy to miss. State-licensed pharmacies do not have to report adverse events to the FDA. So the real total is likely higher than the reports show.
The FDA also flagged the wrong ingredient. Some compounders used salt forms, like semaglutide sodium or semaglutide acetate. The agency says these are different active ingredients from the approved drugs.
Fakes are a real risk too. The FDA is aware of counterfeit Ozempic® in the U.S. supply chain. It has also found fraudulent compounded products with false pharmacy names on the label.
The agency is acting at the border as well. It set up a “green list” import alert for GLP-1 raw ingredients. The goal is to keep poor-quality material out of the U.S. supply.
Two more warnings round out the list. Some compounded shots arrived warm, which can harm quality. Others were sold with “for research use” labels that are not meant for people.
The FDA does not review compounded GLP-1 for safety, effectiveness, or quality before it reaches you.
Red flags to watch on telehealth sites
The FDA lists warning signs for shoppers. If you see one on a site or a label, slow down. These are the red flags the agency points to.
- The site claims a compounded version is the same as an FDA-approved drug.
- It pushes deals that seem too good to be true.
- It ships medicine with no clear instructions, or in damaged packaging.
- It does not require a screening and prescription from a licensed doctor.
- No licensed doctor is available to answer questions after your order arrives.
- The label has spelling errors, a wrong address, or a pharmacy name you cannot verify.
Compounded vs the FDA-approved branded products
It helps to see the two side by side. The table below compares them on approval, testing, and what the FDA says. The focus here is approval and safety, not cost.
| What to compare | FDA-approved branded product | Compounded semaglutide or tirzepatide |
|---|---|---|
| FDA approval | Yes, after full FDA review | No FDA approval |
| Safety and quality testing | Reviewed by the FDA before sale | Not reviewed by the FDA before sale |
| What the FDA says | Meets FDA standards for safety, effectiveness, and quality | Use only if an approved drug cannot meet your medical need |
| Clinical trial results | Backed by named trials like STEP and SUSTAIN | Trial results do not transfer to the compound |
| Examples | Wegovy®, Ozempic®, Mounjaro®, Zepbound® | Compounded semaglutide, compounded tirzepatide |
The trial numbers belong to the brands. In the STEP 1 trial, adults on Wegovy® lost about 14.9% of body weight over 68 weeks (N=1,961, Wilding 2021). Wegovy® is the brand of semaglutide approved for weight.
That result is tied to the FDA-approved branded product. It does not transfer to compounded semaglutide. A compounded copy was never the product in that trial.
Why “not FDA-approved” matters?
It is easy to skip past those three words. But they carry a lot of weight. “Not FDA-approved” means no agency check on safety, effectiveness, or quality before sale.
That gap can show up in the vial. Strength and purity may vary from one batch to the next. You cannot be sure the dose matches the label.
The FDA points to a safer path. Get a prescription from your own doctor, and fill it at a state-licensed pharmacy. Its BeSafeRx program shares ways to buy medicine online safely.
The FDA offers a plain rule of thumb. Compounded drugs should be used only when an FDA-approved drug cannot meet your medical need. A licensed clinician helps make that call.
For the broader picture, the general guide compares compounded and approved drugs at /learn/compounded-vs-fda-approved/. This page stays focused on GLP-1 and the FDA’s position.
The Bottom Line
Here is the simple map. Compounded semaglutide and tirzepatide are not FDA-approved, and not a generic of Wegovy®, Ozempic®, Mounjaro®, or Zepbound®. The FDA does not check them for safety, effectiveness, or quality before sale.
The shortage that fueled them is over. Both drugs came off the shortage list, and the FDA’s pause on enforcement ended in 2025. Making near-identical copies is now limited.
So bring this to a licensed clinician. Ask about the approved brands, the real risks, and your options. That turns a confusing ad into a safe, clear plan.
FREQUENTLY ASKED QUESTIONS
No, it is not. It is compounded semaglutide, which is not FDA-approved and not a generic of Wegovy® or Ozempic®. The FDA does not review it for safety, effectiveness, or quality before sale, and trial results for the branded products do not transfer. Ask a licensed clinician detailed questions before you weigh one.
The rules tightened after the shortage ended. While a drug is in shortage, pharmacies can compound copies under limited rules. The FDA declared the semaglutide shortage resolved on February 21, 2025, and its pause on enforcement ended later that year. Making near-identical copies is now restricted, so ask a licensed pharmacy what applies to you.
It grew out of a supply shortage. Semaglutide and tirzepatide went into shortage in 2022 as demand climbed. Federal law lets pharmacies compound a copy while a drug sits on the FDA shortage list. Telehealth sites used that window, which is when many people first saw these ads.
The FDA has flagged several problems. It received adverse-event reports tied to dosing errors, some serious enough for a hospital visit. It warned about salt forms like semaglutide sodium, which are different active ingredients. It is also aware of counterfeit Ozempic® and fraudulent compounded products, and you can report any problem to FDA MedWatch.
They are salt forms of semaglutide. The FDA says these are different active ingredients from the ones in the approved drugs. The agency does not have data showing they act the same way, and it sees no lawful basis for using them in compounding. That is why the salt forms raise a red flag.
No, they do not. Those trials studied the FDA-approved branded products, not compounded copies. In STEP 1, adults on Wegovy® lost about 14.9% of body weight over 68 weeks. That result belongs to the branded product, not to compounded semaglutide, which was never the product tested.
Start with the brand name and the label. FDA-approved options include Wegovy®, Ozempic®, Mounjaro®, and Zepbound®. A compounded product will not carry FDA approval, so be cautious if a site claims a compounded version is the same as an approved drug. A licensed clinician or pharmacist can confirm.
Availability has narrowed since the shortage ended. Some pharmacies may still compound in specific cases, such as a documented medical need that an approved drug cannot meet. But broad compounding of copies is now restricted. If a site still offers it freely, treat that as a reason to ask more questions.
Keep Reading
The best GLP-1 providers, compared
Now you know what the FDA says about compounded GLP-1. Next, see how the top telehealth providers compare on access, support, and pricing transparency.
→ Read next: /compare/best-glp1-programs/
SOURCES
1. US Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. CDER Update, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
2. US Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
3. US Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
4. US Food and Drug Administration. Declaratory Order: Resolution of Shortages of Tirzepatide Injection Products. 2024. https://www.fda.gov/media/184606/download
5. US Food and Drug Administration. Declaratory Order: Resolution of Shortages of Semaglutide Injection Products. 2025. https://www.fda.gov/media/185526/download
6. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
Last updated: 2026-07-10 · Editorially reviewed by the Peptides.io team
Important notices & disclaimers
Editorial & medical: This guide is general education, not medical advice. Talk to a licensed clinician before starting, stopping, or changing any medication.
Affiliate disclosure: Peptides.io may earn a commission from links to providers — it never changes what you pay or how we rank them, and never influences our recommendations.
Compounded GLP-1 (FDA): Compounded semaglutide and tirzepatide are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality. They are not generic versions of, or equivalent to, branded medications such as Ozempic®, Wegovy®, Mounjaro®, or Zepbound®. Clinical-trial results cited here apply only to those branded formulations — not to compounded preparations.
Comments